ANTXR2 and cancer: However, for CMG2, there are mixed reports of the effect of its overexpression on cancer progression; some show that lower CMG2 correlated with a more aggressive soft-tissue sarcoma58 and breast cancer59, and others reveal that higher CMG2 resulted in a worse survival rate in patients with gastric cancer60 and glioblastoma61.